CVS beats estimates, hikes adjusted profit outlook on retail pharmacy and insurance unit strength

CVS Health reported strong second-quarter results, exceeding analyst expectations with adjusted earnings per share of $1.81 and revenue of $98.92 billion, driven by robust performance in its retail pharmacy business and an improving Aetna insurance unit. The company raised its fiscal 2025 adjusted profit outlook to $6.30-$6.40 per share, signaling increased confidence in its operational improvements and ongoing turnaround initiatives. Despite persistent elevated medical costs impacting its insurance segment's profitability, this positive earnings surprise and guidance hike led to a significant premarket stock increase, reflecting investor optimism in CVS's strategic direction under CEO David Joyner.

Analysis

CVS Health delivered a significant second-quarter beat, with adjusted EPS of $1.81 surpassing estimates of $1.46 and revenue of $98.92 billion exceeding the $94.50 billion consensus. This outperformance, driven by revenue growth across all three business segments, prompted management to raise its fiscal 2025 adjusted profit outlook to $6.30-$6.40 per share. The retail pharmacy business was a key driver, with sales up over 12% to $33.58 billion, attributed to new technology and an updated drug pricing model. However, significant profitability headwinds persist, evidenced by a year-over-year decline in net income to $1.02 billion from $1.77 billion and a cut to GAAP earnings guidance. The core challenge remains within the Aetna insurance unit, where the medical benefit ratio (MBR) deteriorated to 89.9% from 89.6% due to elevated medical costs. While this was better than the 90.6% analysts feared, the company booked a $471 million premium deficiency reserve, signaling anticipated losses in its 2025 Medicare plans and underscoring the ongoing nature of its "multi-year recovery effort" in the insurance segment.

Key Decisions for Investors

• The strong earnings beat and raised adjusted guidance signal that the operational turnaround may have positive momentum, potentially justifying a more constructive view on the stock in the near term.
• Investors should closely monitor the Aetna insurance unit's profitability, specifically the Medical Benefit Ratio and any updates on the premium deficiency reserve, as this remains the primary risk to sustained earnings growth.
• The divergence between the raised adjusted EPS guidance and the cut to GAAP earnings warrants careful scrutiny of the underlying non-GAAP adjustments to assess the true quality and sustainability of the company's profitability.
• Consider the successful execution of the $2 billion cost-cutting plan and the performance of the new pharmacy pricing model as key long-term catalysts that could offset structural margin pressure from the insurance business.